Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Financial Results For The Quarter And Nine Months Ended December 31, 2022

 With reference to the intimation of Board meeting submitted on January 16, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 31, 2023 which commenced at 10:00 a.m. and ended at 01:20 p.m. The Board has, inter-alia, Approved Financial Results for the quarter and nine months ended December 31, 2022 Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company and its subsidiaries for the quarter and nine months ended December 31, 2022, along with the Limited Review Reports thereon.
31-01-2023

Sun Pharma buys Disperzyme, Phlogam brands from Aksigen Hospital Care

 All three brands are approved by the DCGI for post-operative inflammation in patients undergoing minor surgery and dental procedures
30-01-2023

Sun Pharma profit may decline 10% in Q3 on poor operating performance

 Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.
30-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release relating to acquisition of Disperzyme(r) and Phlogam(r) brands in India.
30-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Outcome Of Postal Ballot And Disclosure Of Voting Results

 The Company vide Postal Ballot Notice dated December 16, 2022 ('Notice'), conducted Postal Ballot seeking approval of the shareholders, by way of a Special Resolution, for appointment of Mr. Sanjay Asher (DIN: 00008221) as an Independent Director of the Company for a term commencing from November 1, 2022 till March 31, 2025. We wish to inform that the appointment of Mr. Sanjay Asher (DIN: 00008221) as an Independent Director of the Company for a term commencing from November 1, 2022 till March 31, 2025, has been approved by the shareholders by way of a Special Resolution.
27-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corrigendum To Our Intimation Dated December 23, 2022 For Filing Of Sustainability Report 2021-22

 Corrigendum to our intimation dated December 23, 2022 for filing of Sustainability Report 2021-22
27-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
27-01-2023

Sun Pharmaceutical launches phenobarbital sodium injection in US

 SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.
25-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Sun Pharma Launches SEZABY(tm) (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures.
25-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
22-01-2023
Next Page
Close

Let's Open Free Demat Account